Chromatographic determination of some biomarkers of liver cirrhosis and hepatocellular carcinoma in Egyptian patients

被引:26
|
作者
Osman, Diaa [1 ]
Ali, Omnia [2 ]
Obada, Manar [1 ]
El-Mezayen, Hatem [2 ]
El-Said, Hala [1 ]
机构
[1] Menoufia Univ, Natl Liver Inst, Dept Clin Biochem, Al Minufiyah, Egypt
[2] Helwan Univ, Dept Chem, Fac Sci, Cairo, Egypt
关键词
gas chromatography; mass spectrometry; hepatocellular carcinoma; liver cirrhosis; metabolomic profile; principle components analysis; MASS-SPECTROMETRY; CANCER; URINE; METABOLOMICS; METABOLISM; PROLIFERATION; SPECTROSCOPY; ACTIVATION;
D O I
10.1002/bmc.3893
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Metabolomics has been shown to be an effective tool for disease diagnosis, biomarker screening and characterization of biological pathways. A total of 140 subjects were included in this study; urine metabolomes of patients with liver cirrhosis (LC, n=40), patients with hepatocellular carcinoma (HCC; n=55) and healthy male subjects (n=45) as a control group were studied. Gas chromatography/mass spectrometry-based urine metabolomics profiles were investigated for all participants. Diagnostic models were constructed with a combination of marker metabolites, using principal components analysis and receiver operator characteristic curves. A total of 57 peaks could be auto-identified of which 13 marker metabolites (glycine, serine, threonine, proline, urea, phosphate, pyrimidine, arabinose, xylitol, hippuric acid, citric acid, xylonic acid and glycerol) were responsible for the separation of HCC group from healthy subjects. Also, eight markers metabolites (glycine, serine, threonine, proline, citric acid, urea, xylitol and arabinose) showed significant differences between the LC group and healthy subjects. No significant difference was detected between HCC and LC groups regarding all these metabolites. Metabolomic profile using GC-MS established an optimized diagnostic model to discriminate between HCC patients and healthy subjects; also it could be useful for diagnosis of LC patients. However, it failed to differentiate between HCC and LC patients.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] EARLY DIAGNOSTICS OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH LIVER CIRRHOSIS BY NOVEL MOLECULAR SPECTROMETRIC BIOMARKERS IN BLOOD PLASMA
    Hribek, Petr
    Habartova, Lucie
    Kubickova, Kristyna
    Koula, Michal
    Syslova, Kamila
    Setnicka, Vladimir
    Urbanek, Petr
    HEPATOLOGY, 2021, 74 : 686A - 686A
  • [22] Predictors of outcome of liver transplantation in patients with liver cirrhosis and hepatocellular carcinoma
    Nicolini, G
    Merli, M
    Gentili, F
    Indrio, G
    Iappelli, M
    Rossi, M
    Berloco, P
    Di Tondo, U
    Muda, AO
    Corradini, SG
    Walter, N
    Attili, AF
    JOURNAL OF HEPATOLOGY, 2004, 40 : 52 - 52
  • [23] MicroRNAs as Plasma Biomarkers of Hepatocellular Carcinoma in Patients with Liver Cirrhosis-A Cross-Sectional Study
    Zenlander, Robin
    Salter, Hugh
    Gilg, Stefan
    Eggertsen, Gosta
    Stal, Per
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (04)
  • [24] Liver transplantation for unresectable hepatocellular carcinoma in patients without liver cirrhosis
    Mergental, Hynek
    Porte, Robert J.
    TRANSPLANT INTERNATIONAL, 2010, 23 (07) : 662 - 667
  • [25] Liver resection and liver transplantation for hepatocellular carcinoma in patients with cirrhosis.
    Gugenheim, J
    Baldini, E
    Casaccia, M
    Ouzan, D
    SaintPaul, MC
    Mouiel, J
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 1997, 21 (8-9): : 590 - 595
  • [26] Programmed death-ligand 1 (PD-L1) polymorphisms as predictive biomarkers for the development of liver cirrhosis and hepatocellular carcinoma in HCV Egyptian patients
    Hassan, Marwa
    Attia, Mohammed Saad
    Ali-Eldin, Zainab
    El Attar, Gamal
    Elzallat, Mohamed
    Saad, Hany Haroun Kaisar
    Isaac, Amira
    TUMOUR VIRUS RESEARCH, 2022, 14
  • [27] Serum Proteoglycans as Prognostic Biomarkers of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis
    Nault, Jean-Charles
    Guyot, Erwan
    Laguillier, Christelle
    Chevret, Sylvie
    Ganne-Carrie, Nathalie
    N'Kontchou, Gisele
    Beaugrand, Michel
    Seror, Olivier
    Trinchet, Jean-Claude
    Coelho, Jessica
    Lasalle, Philippe
    Charnaux, Nathalie
    Delehedde, Maryse
    Sutton, Angela
    Nahon, Pierre
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2013, 22 (08) : 1343 - 1352
  • [28] Impact of Cirrhosis on the Choice of Liver Resection in Patients with Hepatocellular Carcinoma
    Zeindler, J.
    Hess, G. F.
    von Heesen, M.
    Aegerter, N.
    Reber, C.
    Schmitt, A.
    Muenst, S.
    Bolli, M.
    Soysal, S. D.
    Kollmar, O.
    BRITISH JOURNAL OF SURGERY, 2023, 110 (SUPP 5) : V5 - V5
  • [29] Outcome after liver transplantation in patients with cirrhosis and hepatocellular carcinoma
    Rossi, M.
    Merli, M.
    Lai, Q.
    Gentili, F.
    Mennini, G.
    Bussotti, A.
    Pugliese, F.
    Della Pietra, F.
    Poli, L.
    Novelli, G.
    Giusto, M.
    Corradini, S. Ginanni
    Lappelli, M.
    Muda, A. Onetti
    Di Tondo, U.
    Gossettil, F.
    Attili, A. F.
    Berloco, P. B.
    TRANSPLANTATION PROCEEDINGS, 2007, 39 (06) : 1895 - 1897
  • [30] Helicobacter pylori seroprevalence in patients with cirrhosis of the liver and hepatocellular carcinoma
    Leone, N
    Pellicano, R
    Brunello, F
    Cutufia, MA
    Berrutti, M
    Fagoonee, S
    Rizzetto, M
    Ponzetto, A
    CANCER DETECTION AND PREVENTION, 2003, 27 (06): : 494 - 497